Understanding how prostate cancer progresses and becomes resistant to treatment
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance
This study is looking into how prostate cancer grows and becomes resistant to common treatments, with the goal of finding new ways to help patients by understanding the role of certain cells and signals in the cancer's survival.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10771142 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind prostate cancer progression and the development of resistance to androgen ablation therapy, which is commonly used to treat this disease. It focuses on the role of specific signaling pathways and cancer stem cells in the survival and proliferation of prostate cancer cells. By identifying key targets that maintain these cancer stem cells, the research aims to develop new therapeutic strategies that could improve treatment outcomes for patients. The approach includes biochemical assays and cellular studies to explore these pathways in detail.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, particularly those who have developed castration-resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone androgen ablation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target and eliminate resistant prostate cancer cells, improving survival rates for patients.
How similar studies have performed: Previous research has shown promise in targeting cancer stem cells and signaling pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Lin, Hui-Kuan — Duke University
- Study coordinator: Lin, Hui-Kuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.